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Abstract. The solubility of seven pharmaceutical compounds (parac-
etamol, benzoic acid, 4-aminobenzoic acid, salicylic acid, ibuprofen,
naproxen and temazepam) in pure and mixed solvents as a function of
temperature is calculated with SciPharma, a semi-empirical approach
based on PC-SAFT, and the NRTL-SAC model. To conduct a fair
comparison between the approaches, the parameters of the compounds
were regressed against the same solubility data, chosen to account for
hydrophilic, polar and hydrophobic interactions. Only these solubility
data were used by both models for predicting solubility in other pure
and mixed solvents for which experimental data were available for com-
parison. A total of 386 pure solvent data points were used for the com-
parison comprising one or more temperatures per solvent. SciPharma is
found to be more accurate than NRTL-SAC on the pure solvent data
used especially in the description of the temperature dependence. This is
due to the appropriate parameterization of the pharmaceuticals and the
temperature-dependent description of the activity coefficient in PC-
SAFT. The solubility in mixed solvents is predicted satisfactorily with
SciPharma. NRTL-SAC tends to overestimate the solubility in aqueous
solutions of alcohols or shows invariable solubility with com-position in
other cases.
1 Introduction
The solubility of active pharmaceutical ingredients (API) needs to be known at dif-
ferent stages of the product and process development. At early stages, solubility and
other important parameters for drug bioavailability such as ionization, permeability
and lipophilicity are screened for the drug-likeness of new pharmaceutical molecules.
At later stages of process development and optimization, the appropriate selection of
solvents and the variation of solubility with temperature are critical for the crystal-
lization and the process design of manufacturing. Therefore, the solubility in a large
number of solvents and mixtures is needed to be known with reasonable accuracy.
Pharmaceutical companies measure the solubility in several solvents and mixtures
and subsequently use these data to feed thermodynamic models capable of correlat-
ing solubility data of pharmaceuticals. Thus, they reduce the number of experiments
needed to screen solvents.
Although there are many models for calculating phase equilibrium, few of them
are designed for solid-liquid equilibrium (SLE) calculations. The models for phase
equilibrium can generally be divided into two types: equation of state (EoS) models
like cubic equations and higher order, and activity coefficient models like NRTL [1],
and UNIFAC [2]. There are some important difficulties in the representation of the
liquid and solid phase, especially when complex molecules as APIs are involved. For
solubility predictions, models have to take into account the weakest intermolecular
interaction (vdW) as well as hydrogen bonding in the liquid phase in the case of
big and complex molecules including many chemical groups. Models that have been
used to correlate SLE data include UNIFAC, the NRTL segment activity coefficient
(NRTL-SAC) model [3], the PC-SAFT EoS [4], the lattice model non-random hydro-
gen bonding theory (NRHB) [5] and the conductor-like screening model (COSMO-RS)
[6,7].
Gracin et al. [8] used UNIFAC to calculate the solubility of solid organic com-
pounds in water and organic solvents. They concluded that the additive assumption
of the approach is not sufficiently accurate since properties of a functional group de-
pend on the rest of the molecule. Hahnenkamp et al. [9] compared UNIFAC, modified
UNIFAC (Dortmund) [10] and COSMO-RS for three pharmaceutical molecules. They
reported that the UNIFAC methods were more accurate than COSMO-RS and that
modified UNIFAC was able to predict the solvent with the highest solubility for two
of the pharmaceuticals. Bouillot et al. [11] used the modification of COSMO-SAC
on the molecule parameterization, and suggested some optimization of the method
[12]. The improvements were promising but the accuracy of the method was still not
convincing, except for quick solubility estimations.
The NRTL-SAC model has been widely used in the pharmaceutical industry the
last decades. It is based on polymer NRTL and correlates satisfactorily experimental
solubility data by using four parameters per molecule. These parameters are concep-
tual segments that describe the effective surface interactions between a solvent and
a solute. They are fitted on experimental solubility data in pure and mixed solvents.
Mullins et al. [13] and Tung et al. [14] compared NRTL-SAC to COSMO-SAC. They
both found that NRTL-SAC that uses experimental data to fit parameters provides
more accurate results for drug solubility. According to Mullins et al. [13] the accu-
racy of COSMO-SAC depends on the molecular conformation but in a non-conclusive
way, i.e., trying different conformers may not improve the accuracy of COSMO-RS.
Mota et al. [15] used A-UNIFAC, UNIFAC and NRTL-SAC to predict solubility in
pure solvents for a set of drug-like molecules. Their suggestion was to use NRTL-SAC
rather than UNIFAC, unless the necessary data for NRTL-SAC are not available.
Sheikholeslamzadeh and Rohani [16] also found better performance of NRTL-SAC
compared to UNIFAC for solubility prediction of pharmaceuticals in pure solvents.
Bouillot et al. [17] compared UNIFAC, NRTL-SAC and COSMO-SAC for five drug
molecules. They found that NRTL-SAC was better than the other models although
predictions were sensitive on the data used for the parameterization. They also ob-
served that all models failed to correctly describe the solubility dependence with
temperature and that an equation of state would be more appropriate for that.
Recently, the PC-SAFT EoS was applied to pharmaceutical solubility calcula-
tions [4,18]. It was shown before [18] that the appropriate parameterization of the
pharmaceuticals based on some experimental data can capture adequately the
solubility in pure and mixed solvents without the need of adjustable parameters.
In the present study, the parameterization scheme for pharmaceuticals has been
extended. Pharmaceuticals are categorized according to their solubility in alcohols
and ketones or esters. Additionally, scaling factors are derived from the solubility
data that feed the model in order to scale the calculated solubility in various
solvents. This empirical approach based on PC-SAFT is called SciPharma and has
been implemented in the MAPS platform of Scienomics.
In this work, we show a comparison between SciPharma and the NRTL-SAC
model. Both models are semi-empirical as they are fed by experimental data. What
is particularly interesting in these models is the possibility to model an API with a
set of parameters and then calculate the solubility in any other solvent or mixture of
solvents. In this work the following seven APIs were considered: paracetamol, ben-
zoic acid, 4-aminobenzoic acid, salicylic acid, ibuprofen, naproxen and temazepam.
To conduct a fair comparison between the models we parameterized the APIs using
the same solubility data on the following solvents: water, methanol, ethanol, ethyl ac-
etate, acetone, cyclohexane. These solvents cover the spectrum of hydrophilic, polar
and hydrophobic interactions needed by both models for appropriate parameterization
of pharmaceuticals. The obtained parameters were then used to calculate solubility
in other pure solvents and mixtures for which we were able to find experimental data
for comparison. The solubility as a function of temperature is, also, examined.
2 Theory
2.1 Solid-liquid equilibrium
Pharmaceuticals are crystalline solids at room temperature. Therefore, the solubility
in a liquid solvent can be described by the solid-liquid equilibrium equation [19]. By
assuming that the solid phase consists of pure pharmaceutical, the following simplified
equation is reached:
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where xi and γi are the mole fraction and the activity coefficient of the pharmaceu-
tical in the liquid solvent. ∆Hm and Tm are the melting enthalpy and temperature,
respectively, R is the gas constant and T the temperature. For the derivation of (1)
it has been assumed that the difference of the pharmaceutical heat capacity in the
solid and liquid phase can be neglected.
Equation (1) shows that the solubility of pharmaceuticals is determined by the
activity coefficient and the pure component properties (the melting enthalpy and
temperature). The activity coefficient is a measure of the non-ideal behavior between
the pharmaceutical and solvent molecules and can be calculated from an appropriate
model, such as NRTL-SAC [3] or PC-SAFT [20].
2.2 NRTL-SAC model
The NRTL-SAC model [3] is a semi-predictive method based on polymer-NRTL [21].
NRTL-SAC characterizes the molecules in terms of conceptual segments. Chen and
Song [3] defined four types of segments: hydrophobic (X), repulsive (Y −) and attrac-
tive (Y +) polar, and hydrophilic (Z). Each component is represented by a quadruplet
[XY −Y +Z] weighing the contribution of each segment. Like in UNIFAC [22], the ac-
tivity coefficient of component I can be written as the sum of a combinatorial and a
residual term:
lnγI = lnγ
C
I + lnγ
R
I . (2)
The combinatorial contribution γCI is calculated from the Flory-Huggins approxima-
tion for the entropy of mixing:
lnγCI = ln
ΦI
xI
+ 1− r1
∑
J
ΦJ
rJ
(3)
where rI and ΦI are the total segment number and the segment mole fraction of
component I, respectively.
The residual term γRI is calculated as the sum of the local composition (lc) inter-
action contribution of each segment [21]
lnγRI = lnγ
lc
I =
∑
k
rk,I
[
lnΓlck − lnΓ
lc
k,I
]
(4)
where lnΓlck and lnΓ
lc
k,I are the activity coefficients of segment k in the mixture and in
the pure component I, respectively.
The segment–segment interaction parameters and the conceptual segment values
of solvents are determined by the regression of experimental vapor-liquid and liquid-
liquid equilibrium data [3]. The segment values for a solute are obtained by the
regression of solubility data in at least four solvents: a hydrophilic one (i.e. water), a
polar attractor (i.e. alcohol), a polar donor (i.e. ketone), and a hydrophobic solvent
(i.e. n-alkane). For a few selected compounds, segment values can be found in the
literature [15,17,23].
Once the segment values of the solute are obtained, they can be used to predict
solubility in other solvents or solvent mixtures. However, the solubility predictions are
very sensitive to the solubility data used for the regression of parameters. A method
for the choice of solvents has been suggested by Bouillot et al. [17].
2.3 SciPharma: a PC-SAFT based approach
The SciPharma approach is based on PC-SAFT. In PC-SAFT the residual Helmholtz
energy ares of a fluid, is written as the sum of the Helmholtz free energy of a refer-
ence fluid and a perturbation term, by using the perturbation theory for fluids. The
reference fluid for PC-SAFT is the hard chain fluid while perturbations account for
dispersion forces and hydrogen bonding:
ares = ahc + adisp + aassoc (5)
where ahc, adisp and aassoc represent the hard chain, dispersion and association terms.
The functional forms for these terms can be found in the original publication [20].
PC-SAFT is extended to mixtures using standard mixing rules [24].
In the context of PC-SAFT each component is described with five parameters
that include the segment number m, the segment diameter σ, the segment dispersion
energy ε/kB , the association energy εhb/kB , and the association volume κhb. The
last two parameters are needed for components that form hydrogen bonds. For the
case of solvents, these parameters are fitted to vapor pressure and saturated liquid
density from low temperature up to close to the critical point. All of the pharmaceu-
ticals examined here contain functional groups that hydrogen bond, either with other
Table 1. Multiplying factors for the actual solubility in water in order to calculate the
target solubility in water used in the parameterization.
Aqueous solubility (mg/g) Multiplying factor
<1.E-03 10000
1.E-03 << 1.E-02 1000
1.E-02 << 1.E-01 500
1.E-01 << 1 100
1 << 10 7.5
>10 10
pharmaceutical molecules or with solvent molecules. For simplicity, all pharmaceuti-
cal molecules are assumed to have 4 associating sites of equal strength (two electron
acceptor and two electron donor). As Ruether and Sadowski [4] pointed out, κhb has a
relatively little effect on the solubility calculations and it was set equal to 0.01. Thus,
the number of pure component parameters for regression practically reduces to four.
The regression of parameters is the most important step for achieving good ac-
curacy in solubility calculations without the need of binary interaction parameters.
The main features of SciPharma that differentiate it from the classical approach with
PC-SAFT are the parameterization of pharmaceuticals and the calculated solubil-
ity that might be scaled depending on the available data. The parameterization of
pharmaceuticals was discussed in [18]. This approach has been further refined in Sci-
Pharma. Pharmaceuticals are classified in families according to their solubility in
polar solvents such as alcohols (methanol, ethanol) and ketones (methyl ethyl ke-
tone, methyl isobutyl ketone) or esters (ethyl acetate). We have, empirically, found
that pharmaceuticals with high solubility in methanol, higher than approximately
30mg/g-solvent belong in the same family. All pharmaceuticals in the present study
belong in this category. For these molecules, the parameterization uses methanol as
the polar solvent. The regression of pharmaceutical parameters requires the solubil-
ity in water, at least one polar solvent and at least one hydrophobic solvent. The
hydrophobic solvent in the present study is cyclohexane. As discussed in [18] the
solubilities in water and in the hydrophobic solvent, used for the regression (target
solubilities), need to be adjusted. The target solubility in water is multiplied by a fac-
tor given in Table 1 depending on the actual solubility in water. The water solubility
affects mainly the size parameters m and σ of the pharmaceutical. By increasing the
target solubility we basically decrease the size of the molecule. Modelling the phar-
maceuticals as small molecules with high interaction energy per segment seems to be
important to capture their solubility in polar and associative solvents. The solubility
in cyclohexane, like in heptane [18], is scaled up to the closest power of 10, i.e., if the
actual solubility is less than 0.1 the target solubility is set to 0.1, if the actual value
is between 0.1 and 1 the target is set to 1, and so on. This might be the necessary
counteraction of the increase in the water solubility. The target solubility in the polar
solvent remains unscaled.
The rest of the solubility data are used in order to screen the multiple parameter
sets produced by the regression against the three solvents (water, methanol, cyclo-
hexane). We will call the three solvents regression solvents and the rest screen solvents.
The parameter set that gives the lowest error for the screen solvents is retained. For
the pharmaceutical family examined in this work, a scaling constant (ScC) is calcu-
lated from the ratio of the experimental solubility in methanol versus the solubility
in ethanol, expressed in mg/g-solvent. ScC is an important parameter for scaling the
solubilities calculated with PC-SAFT for specific solvents. For the family examined in
this work, ScC scales down the calculated solubilities in ketones, namely methyl ethyl
ketone and methyl isobutyl ketone that are commonly used solvents in the pharma-
ceutical industry. The scaling rules described here refer only to the pharmaceutical
family examined in this work. Discussion on other pharmaceutical families will be the
subject of another publication.
Apart from ScC that is characteristic for each pharmaceutical, scaling factors are
also calculated for the screen solvents as the ratio of the experimental value and the
calculated value with the retained parameter set for the pharmaceutical. The parame-
ter set might not reproduce exactly the solubility in the screen solvents. Therefore, the
ratios between the calculated and the experimental values are calculated to correct
accordingly the calculated solubilities. These can be thought as effective kij parame-
ters. The ratio of the experimental versus the calculated solubility in ethanol scales
also the calculated solubilities of higher alcohols up to butanol. It has been observed
that for higher, than butanol alcohols, scaling the calculated values does not improve
the prediction. The scaling factor for ethyl acetate (experimental versus calculated
value) scales also the calculated solubility in other esters like propyl acetate. Thus,
the available solubility data are used to improve the predictions in other solvents of
the same family. The classification for the solvent families is empirical and does not
rely necessarily on the chemical families. It has been built on the compilation of avail-
able data. If no relevant data are provided, the scaling ratio is equal to one. Finally,
the elevated solubility in the hydrophobic solvent, used for the regression, needs to
be scaled down to the actual value. The correction also applies to other hydrophobic
solvents like hexane, heptane and so on.
For calculating the solubility in aqueous mixtures, the high solubility in water im-
posed by the parameterization scheme needs to be brought down to its original value.
For this purpose, a binary interaction parameter kij between the pharmaceutical and
water is used [18]. The scaling factors calculated for the pure solvents are transferred
also to the mixtures. For mixed solvents at specific composition the calculated solubil-
ity is scaled by the arithmetic average of the scaling factors for the solvents weighted
by the molar composition of the mixture. For aqueous mixtures, the scaling factor for
water is taken equal to the ScC of the pharmaceutical.
3 Computational details
In this paper, paracetamol, benzoic acid, 4-aminobenzoic acid, salicylic acid, ibupro-
fen, naproxen and temazepam were chosen as model drugs. The chemical structure of
these molecules is shown in Figure 1. The choice was based on the chemical diversity
they offer because of the various functional groups they contain and the numerous
solubility data available in the literature for these molecules.
The melting temperature and enthalpy of these molecules are listed in Table 2.
Some of these data were measured previously [17] by some of the authors of this work.
Uncertainties are also provided when available, in parenthesis. The same solubility
data were used for both SciPharma and NRTL-SAC. More specifically, the solubility
in water, methanol, ethanol, ethyl acetate, acetone and cyclohexane at 298.15K were
used. These data are given in Table 3. The selected solvents cover the spectrum of
hydrophilic, polar and hydrophobic solvents needed for adequate parameterization of
the solutes for both models.
The calculations with SciPharma were conducted within the MAPS platform of
Scienomics. The parameters of the pharmaceuticals calculated with SciPharma are
given in Table 4. In the same table are listed the parameters of some of the solvents
used in the solubility calculations for which the parameters were regressed in this
work by using vapor pressure data and saturated liquid densities. The temperature
range of the regression and the resulting average absolute deviation (%) are also given
in Table 4. The parameters for ethyl acetate, acetone, 1,4-dioxane, n-butyl acetate,
Fig. 1. Chemical structure of the pharmaceuticals examined in this work: (a) paracetamol,
(b) benzoic acid, (c) p-aminobenzoic acid, (d) salicylic acid, (e) ibuprofen, (f) naproxen and
(g) temazepam.
Table 2. Melting temperature and enthalpy for the pharmaceutical compounds examined
in this work. Uncertainties, when available, are given in parenthesis.
Compounds Tm(K) ∆Hm(J/mol)
Paracetamol [17] 442.1 (0.5) 27471 (1720)
Benzoic acid [17] 395.2 (0.3) 17350 (775)
p-Aminobenzoic acid [42] 461.7 24030
Salicylic acid [17] 431.4 (0.1) 24626 (2652)
Ibuprofen [17] 347.9 (0.7) 25204 (1577)
Naproxen [42] 427.6 31500
Temazepam [40] 432.5 25581
methyl ethyl ketone, methyl isobutyl ketone and propylene glycol were taken from
previous work [18]. For the rest of the solvents used in this work the parameters were
taken from [20] and [25].
The quadruplets [XY −Y +Z] of NRTL-SAC were regressed with the help of the
lsqnonlin function of Matlab and are listed in Table 5 along with the regression error.
The error is calculated with an equation similar to (6) except that mole fractions
were used instead of their logarithms.
4 Results and discussion
4.1 Pure solvents
The solubility of the pharmaceuticals in various solvents at different temperatures was
calculated with both SciPharma and NRTL-SAC. The results are compared against
Table 3. The solubility data at 298.15K used for the regression of pharmaceutical parameters with both models. Data are given in mole
fraction units.
Regression solvents Paracetamol Benzoic acid p-Aminobenzoic acid Salicylic acid Ibuprofen Naproxen Temazepam
Water 1.77E-03 5.00E-04 7.75E-04 2.88E-04 1.36E-05 5.13E-06 6.10E-06
Methanol 6.58E-02 0.1632 4.73E-02 1.28E-01 *2.14E-01 1.46E-02 5.47E-03
Ethanol 6.01E-02 0.1789 4.47E-02 1.39E-01 1.98E-01 2.01E-02 3.00E-03
Ethyl acetate 5.48E-03 0.165 5.32E-02 1.36E-01 2.25E-01 3.55E-02 1.45E-02
Acetone 3.69E-02 0.1925 4.84E-02 1.79E-01 2.33E-01 6.92E-02 2.07E-02
Cyclohexane 2.00E-05 0.012 1.20E-05 4.30E-04 1.12E-01 1.20E-04 1.58E-03
* Solubility at 303.15K.
Table 4. PC-SAFT parameters for the pharmaceutical compounds and solvents regressed in this work. The temperature range and the average
absolute deviation (%) of the regression are also listed for the solvents.
Compounds m σ(A˚) ε/k (K) N assoc εhb/k (K) khb T (K) ∆P
sat (%) ∆ρliq (%)
Paracetamol 1.5210 4.3806 388.53 4 1783.97 0.01
Benzoic acid 2.3221 3.5626 247.82 4 946.93 0.01
p-Aminobenzoic acid 3.5807 4.0700 400.65 4 1930.94 0.01
Salicylic acid 1.5364 4.7402 349.88 4 1349.85 0.01
Ibuprofen 3.6175 3.4231 256.78 4 1148.89 0.01
Naproxen 3.8212 3.8088 354.09 4 1408.52 0.01
Temazepam 4.7180 3.6069 356.57 4 1265.82 0.01
Solvents
Acetic acid 1.5026 3.7014 286.12 1 5248.62 0.0067 293–563 1.21 0.084
Acetic anhydride 4.2175 3.1329 250.93 – – – 220–562 0.37 1.75
Acetophenone 3.8408 3.4574 219.26 2 1952.05 0.9632 295–680 1.33 0.7
Anisole 3.3319 3.5611 290.17 2 498.46 0.0252 250–610 0.92 0.43
Benzyl alcohol 5.7211 2.9154 226.99 2 983.98 1.2718 265–555 0.81 1.48
2-Butanol 2.9580 3.5012 240.75 2 2123.63 0.0141 170–500 1.57 1.39
Carbon tetrachloride 2.3182 3.8116 292.55 – – – 200–490 0.16 0.42
Chloroform 2.3767 3.5406 278.63 2 811.02 0.0033 220–505 0.79 0.55
Dichloromethane 1.9808 3.4966 292.93 2 1032.41 0.0034 200–485 0.64 1.55
Diethyl ether 2.8662 3.5531 223.75 2 1097.99 9.8E-04 170–440 0.06 0.34
Dimethyl sulfoxide 3.6364 2.9678 209.18 2 2259.18 1.0484 293–630 1.26 0.59
Dimethylformamide 3.5169 3.1019 211.69 2 1564.27 1.4000 240–580 0.75 0.86
Ethylene glycol 1.9088 3.5914 325.23 4 2080.03 0.0235 270–610 0.75 2.1
Methyl acetate 3.1994 3.1723 233.35 2 1056.84 1.7E-04 200–480 0.38 0.8
2-Methyl-1-propanol 2.4236 3.7659 264.16 2 2811.02 0.0033 200–500 1.13 0.35
N-Methyl-2-pyrrolidone 3.6473 3.3241 242.18 2 1658.75 1.0979 260–675 0.37 0.28
Tetrahydrofuran 3.1437 3.2217 196.28 2 733.27 1.0979 180–520 0.69 0.18
Table 5. The NRTL-SAC segments for the pharmaceutical compounds. The error of the
regression is listed in the last column (*RMSE calculated from mole fractions instead of
their logarithms).
Compounds X Y - Y + Z RMSE(∗)
Paracetamol 0.369 0.88 0.392 0.659 0.066
Benzoic acid 0.53 0 0.396 0.493 0.003
p-Aminobenzoic acid 0.122 1.115 2.235 0.388 0.108
Salicylic acid 0.844 2.216 0.664 0 0.003
Ibuprofen 0.889 0.55 0.38 0.063 0.025
Naproxen 0.653 0.046 1.25 0.653 0.008
Temazepam 0.415 0 1.58 0 0.565
Table 6. The RMSE of the two models for the solubility of the compounds in pure sol-
vents. A total of 386 data points were considered comprising pure solvents at one or more
temperatures. The data used for parameterization were excluded.
Compounds Data points RMSE RMSE
(SciPharma) (NRTL-SAC)
Paracetamol 69 0.181 0.219
Benzoic acid 87 0.160 0.136
p-Aminobenzoic acid 30 0.260 0.319
Salicylic acid 63 0.158 0.306
Ibuprofen 95 0.158 0.129
Naproxen 29 0.362 0.452
Temazepam 13 0.470 0.498
Average 0.196 0.227
experimental data for paracetamol [26–28], benzoic acid [29–31], p-aminobenzoic acid
[32], salicylic acid [32–35], ibuprofen [36,37], naproxen [38,39], and temazepam [40].
A compilation of these data can be found in [41]. Comparison between calculations
and experimental data for all molecules in pure solvents is shown in Figure 2 for
SciPharma (top) and NRTL-SAC (bottom). The average root-mean-squared error
(RMSE) is calculated as follows:
RMSE =
√√√√ 1
N
N∑
i=1
(
logXexpi − logX
calc
i
2
(6)
where Xi is the solubility of the compound i in mole fraction and N is the number
of data points. The RMSE of the models is given in Table 6. The data points used
for the parameterization of the compounds are excluded from Figure 2 and from the
calculation of RMSE in Table 6. The data points are pure solvents at one or more
temperatures for which there were available data. All solvents for which there was
at least one solubility available at some temperature are included in Figure 2. The
solubilities span many orders of magnitude. Almost all results are within one order of
magnitude of the experimental values, as depicted by the parallel lines that set this
boundary. The data are, also, given in tabular form as Supplementary material.
In Figure 2 some outliers stick out from the rest of the data points. For SciPharma,
the points lying on the boundary line and above are paracetamol [27] and salicylic acid
[32] in chloroform (the experimental values are low compared to the prediction). Also,
close to the boundary line with error close to 0.7 or above are the data for temazepam
[40] in dichloromethane and naproxen in 1,4-dioxane [39] and dimethylformamide [38]
(RMSE = 0.66). For these data points the predictions of SciPharma are low compared
Fig. 2. Predicted versus experimental solubility (mole fraction) of the pharmaceutical com-
pounds in various pure solvents at one or more temperatures. Results with SciPharma (top)
and NRTL-SAC (bottom).
to experiment. Solvents like dichloromethane, 1,4-dioxane, or dimethylformamide are
polar solvents that depending on the polar groups of the pharmaceutical may result in
high solubility. To account implicitly for polar interactions and enhance the interac-
tions of polar solvents with the pharmaceuticals which, usually, contain several polar
groups, the solvents were modelled with association sites as can be seen in Table 4.
Nevertheless, the results are not always satisfactory.
For NRTL-SAC, the points lying outside the boundary of one order of magnitude
are paracetamol [27], p-aminobenzoic acid [32] and salicylic acid [32] in chloroform
(low experimental values compared to the prediction), naproxen [38] in heptane (much
lower solubility is predicted) and in ethylene glycol, and temazepam in anisole [40].
As can be seen from the average RSME in Table 6, calculated over 386 data points,
SciPharma is about 13% more accurate than NRTL-SAC. For some solvents for which
there were no available parameters with NRTL-SAC, namely 1-hexanol, 1-heptanol,
2-methyl-1-propanol, methyl acetate, propylene glycol, diethyl ether, benzyl alcohol,
acetophenone, acetic anhydride, results are reported only for SciPharma along with
the experimental values. These data points were excluded from the error calculation.
From the error calculation were also excluded the data used for the parameterization
and the solubilities of paracetamol and salicylic acid in chloroform for which the
deviation of NRTL-SAC exceeds 4 orders of magnitude. All data are given in the
Supplementary material.
One reason for the better accuracy achieved by SciPharma is that temperature-
dependent results of solubility are included and this is described better by PC-SAFT
since the activity coefficient is temperature-dependent while in NRTL-SAC the tem-
perature dependence is not built in. The temperature dependence is depicted in
Figure 3 where solubility data for selected compounds are plotted for some solvents
in a range of temperatures. In each plot the same color/symbol points correspond
to the same solvent at different temperatures. The correct qualitative description of
solubility as a function of temperature would result in points lying on a line paral-
lel to the diagonal line. The deviation of each model from the correct description of
temperature dependence is calculated as the difference of the slope of the calculated
versus experimental solubility curve from 1 (slope of the diagonal):
Dev = 1−
dXpred
dXexp
· (7)
The slopes were calculated with linear regression. The average deviation for each
pharmaceutical is given in Table 7 for both models. The solvents over which the
deviation was calculated are also listed. On the average, the deviation for SciPharma
is 30% smaller compared to NRTL-SAC. The data can be found in the Supplementary
material.
4.2 Mixed solvents
The predictive ability of the models was, subsequently, tested on solubility calcula-
tions in mixed solvents. As the solubility in pure solvents spans many orders of mag-
nitude (Fig. 2) one expects that for selected mixed solvents the solubility will vary
substantially as a function of composition. In the pharmaceutical industry a mixed
solvent is commonly used to tune solubility. From this point of view a thermodynamic
model capable to predict the variation of solubility is highly desirable.
Standard mixing rules were used for PC-SAFT [24]. Also, for aqueous mixtures,
a kij parameter between the pharmaceutical and water was used to bring down to its
actual value the elevated solubility in water due to the parameterization scheme. The
scaling factors calculated for pure solvents are also used for mixtures. These factors
can be thought as effective binary interaction parameters kij. As we discussed above,
the calculated solubility with PC-SAFT at any composition is scaled with the molar
average of the scaling factors of the two solvents. For water the scaling constant (ScC)
characteristic of each pharmaceutical is used. Finally, no binary parameter was used
for the interactions between the solvents.
Some typical examples are shown in Figure 4 to Figure 6. Figure 4 shows compar-
ison between experimental solubility data of paracetamol [43] and naproxen [44] in
ethanol/water with both models. To correct the solubility in water with SciPharma,
binary interaction parameters kij are calculated from the actual solubility of parac-
etamol and naproxen in water as 0.04803 and 0.071, respectively. Ethanol is one
Fig. 3. Predicted versus experimental solubility (mole fraction) for selected drugs in pure
solvents at a range of temperatures to illustrate the temperature dependence of solubility.
From top to bottom are shown: paracetamol, benzoic acid, salicylic acid, ibuprofen with
SciPharma (left) and NRTL-SAC (right).
Table 7. The deviation of the two models from the correct description of temperature
dependence as calculated from (7). The solvents considered for the deviation estimation are
listed.
Compounds Solvents Dev Dev
(SciPharma) (NRTL-SAC)
Paracetamol MeOH, EtOH,1-PrOH, 2-PrOH, 0.38 0.70
1-BuOH, Acetone, EtOAc
Benzoic acid EtOH, 2-PrOH, 1-C8OH, 0.13 0.15
Acetone, Acetic acid, Toluene
Salicylic acid MeOH, EtOH, Acetone, Acetic 0.32 0.57
acid, MeCN, EtOAc, Xylene
Ibuprofen MeOH, EtOH, 1-PrOH, 2-PrOH, 0.11 0.07
Acetone, EtOAc, MIBK
Naproxen Cyclohexane, Chloroform, 0.46 0.56
1-C8OH
Average 0.28 0.41
Fig. 4. Experimental and predicted solubility of paracetamol and naproxen in the ethanol
water binary mixture at 298.15K.
of the solvents used for the parameterization, thus, the solubility for this binary is
known at the ends of the phase diagram. The solubility of naproxen spans three or-
ders of magnitude through the entire composition range. Both models seem to predict
qualitatively the solubility variation with composition. NRTL-SAC overestimates the
solubility, especially for naproxen, up to 0.5 ethanol mass fraction.
Figure 5 depicts the solubility of paracetamol in 2-propanol/water. This mixture
was selected because the solubility in 2-propanol is not known by the models. Sci-
Pharma treats 2-propanol with the same scaling factors for ethanol, since they are in
Fig. 5. Experimental and predicted solubility of paracetamol in the 2-propanol/water
mixture at 298.15K.
Fig. 6. Experimental and predicted solubility of salicylic acid in the propanol/water and
1,4-dioxane/water mixtures at 298.15K.
the same family of solvents. The predictions are in good agreement with the experi-
mental data [45]. NRTL-SAC tends to overestimate the solubility especially from low
to intermediate alcohol mass fractions. However, it manages to predict a maximum
of solubility at high propanol concentration (although the maximum is extended to
lower concentrations).
Finally, in Figure 6 are shown the experimental [46,47] and calculated solubili-
ties of salicylic acid in aqueous mixtures of propanol and 1,4-dioxane. Solubility in
pure propanol and 1,4-dioxane solvents is not known to the models. For SciPharma,
similarly to 2-propanol, propanol has a scaling ratio inherited from the known
solubility in ethanol. No scaling factor is used for 1,4-dioxane. The solubility of sali-
cylic acid in water is corrected with a kij parameter equal to 0.038. SciPharma shows
good agreement with the experimental data. It, even manages to predict the slightly
higher solubility in the 1,4-dioxane aqueous solution. NRTL-SAC gives a flat curve
showing no variation of solubility with composition up to about 0.9 water mole frac-
tion with propanol or higher in the case of 1,4-dioxane.
The results in the mixtures show that SciPharma can be used with confidence to
calculate the solubility in mixtures with no other adjustable parameter than the scal-
ing factors derived from the known solubilities in specific solvents. By extending these
factors to other solvents of the same family (propanol, 2-propanol) seems sufficient
for quantitative results. Also, the appropriate parameterization of the pharmaceuti-
cals with the proposed scheme is a key aspect that permits reliable predictions even
without scaling factors (1,4-dioxane).
5 Conclusions
In this work, SciPharma, a PC-SAFT-based approach, and NRTL-SAC model were
used to study the solubility of seven pharmaceutical compounds in pure and mixed
solvents as a function of temperature. For the parameterization of the compounds, the
same solubility data were used for both models. The six solvents involved were chosen
to cover the whole range of hydrophilic, polar and hydrophobic molecules needed for
adequate parameterization with both models. These six solubility data were the only
data used by both models for predicting the pharmaceutical solubility in other pure
and mixed solvents.
The two models were compared against available experimental data. The solubility
in all pure solvents that could be found in literature at a single temperature and
in some solvents in a range of temperatures was captured with an overall better
accuracy of 13% by SciPharma in terms of RMSE. Results from solvents only as a
function of temperature show that SciPharma is more accurate in the description of
the temperature dependence of solubility. The reason for this is that the temperature-
dependence of the activity coefficient is built-in for PC-SAFT.
The solubility in mixed solvents is better predicted with SciPharma. NRTL-SAC
seems to overestimate the solubility in aqueous mixtures of alcohols. In some cases,
NRTL-SAC showed almost invariable solubility with composition. SciPharma man-
ages to predict quantitatively the solubility in mixtures with no other adjustable
parameter than scaling factors derived from the solubility in pure solvents used for
the parameterization.
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